BR100 Increased By (0.12%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.32%)
KSE30 Increased By (0.42%)
AGHA 6.41 Increased By ▲ 0.09 (1.42%)
BECO 4.37 Increased By ▲ 0.10 (2.34%)
BML 63.00 Increased By ▲ 0.55 (0.88%)
BOP 31.50 Increased By ▲ 0.27 (0.86%)
CNERGY 11.69 Increased By ▲ 0.10 (0.86%)
CSIL 5.89 Increased By ▲ 0.17 (2.97%)
FCCL 60.84 Decreased By ▼ -0.70 (-1.14%)
FFL 14.72 Decreased By ▼ -0.30 (-2%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.94 Increased By ▲ 0.38 (6.83%)
LOTCHEM 24.68 No Change ▼ 0.00 (0%)
MLCF 103.25 Decreased By ▼ -0.83 (-0.8%)
NBP 173.10 Decreased By ▼ -2.18 (-1.24%)
NCPL 52.25 Decreased By ▼ -0.52 (-0.99%)
NPL 54.10 Decreased By ▼ -0.02 (-0.04%)
OGDC 316.78 Increased By ▲ 3.39 (1.08%)
PACE 9.20 No Change ▼ 0.00 (0%)
PAEL 35.80 No Change ▼ 0.00 (0%)
PIBTL 13.62 Increased By ▲ 0.15 (1.11%)
PPL 226.60 Increased By ▲ 4.79 (2.16%)
PRL 80.50 Increased By ▲ 1.42 (1.8%)
PTC 46.99 Increased By ▲ 0.14 (0.3%)
SSGC 23.70 Decreased By ▼ -0.17 (-0.71%)
TBL 9.29 Decreased By ▼ -0.02 (-0.21%)
TELE 7.54 Increased By ▲ 0.15 (2.03%)
TPL 24.69 Decreased By ▼ -0.42 (-1.67%)
TPLP 12.87 Increased By ▲ 0.36 (2.88%)
TREET 26.35 Increased By ▲ 0.10 (0.38%)
TRG 53.38 Decreased By ▼ -0.06 (-0.11%)
World

AstraZeneca UK vaccine trial drops sub-group with children: U.S. trial register

  • AstraZeneca, which is developing the vaccine along with the University of Oxford, did not immediately respond to a request for comment.
Published Updated
By

Drugmaker AstraZeneca has removed a study group comprising children from a trial of its COVID-19 vaccine candidate in Britain, clinical trial registers in the United States showed on Monday.

The mid-to-late stage trial of more than 12,000 participants previously included children above the age of five years with the consent of their parents. However, the page was updated on Dec. 10 to reflect the changes.

AstraZeneca, which is developing the vaccine along with the University of Oxford, did not immediately respond to a request for comment.

Comments

Comments are closed for this article.